DiaSorin completes Luminex acquisition for $1.8B

By LabPulse.com staff writers

DiaSorin has completed its acquisition of Luminex in a deal valued at $1.8 billion. The acquisition gives DiaSorin access to Luminex's multiplexing technology, while also expanding the Italian company's footprint in the U.S.

DiaSorin first announced the acquisition in April 2021, saying that the deal would position the company as a full-fledged provider of products in both the diagnostics and life sciences segments. DiaSorin said that it sees Luminex's clinical multiplexing assays as a major asset in helping the company position itself as a provider to biopharma companies.

Copyright © 2021 LabPulse.com

To read this and get access to all of the exclusive content on LabPulse.com, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a LabPulse.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?